CrushSCI.com
125.7Average days
111Median days
2Fastest days
296Longest days
1402025 publications

Paper Review Records

All Paper Review Records

27 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

93 days

Pharmacokinetic Interaction Between Eperisone and Ojeok‐San in Healthy Subjects

Authors
Do Hoon Keum; Minkyu Choi; Kyoung Hoon Mo; Sukyong Yoon; Min Soo Park; Young Woo Kim; Won‐Yung Lee; Choon Ok KimShow moreShow less
Affiliations
1. Department of Clinical Pharmacology Severance Hospital Yonsei University Health System Seoul Republic of Korea; 2. Department of Pharmaceutical Medicine and Regulatory Sciences Colleges of Medicine and Pharmacy Yonsei University Incheon Republic of Korea; 3. Department of Pediatrics Yonsei University College of Medicine Seoul Republic of Korea; 4. School of Korean Medicine Dongguk University Gyeongju Republic of Korea; 5. School of Korean Medicine Wonkwang University Iksan Republic of KoreaShow moreShow less
Source PDF DOI Publisher page
111 days

Pharmacokinetic and Bioequivalence of Mirtazapine Orally Disintegrating Tablets: A Randomized, Crossover Study

Authors
Kai Bin Liew; Kar Ming Yee; Jeyashanthini Nalaiya; Atiqah Amran; Khairil Aswad OthmanShow moreShow less
Affiliations
1. Department Faculty of Pharmacy University of Cyberjaya (UoC). Cyberjaya Selangor Malaysia; 2. Formulation and R&D Technologies Duopharma Innovation Sdn. Bhd. Shah Alam Selangor Malaysia; 3. Questra Bio‐Clinical Research Centre Questra Clinical Research Sdn. Bhd., Permatang Pauh Pulau Pinang MalaysiaShow moreShow less
Source PDF DOI Publisher page
175 days

A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia

Authors
Longxia Chen; Ruilin Ding; Yuanwei Chen; Xinghai Li; Tengqiong Xiong; Hong Chen; Xiaojing Hu; Yi Zhou; Feng Jiang; Qing PengShow moreShow less
Affiliations
1. Institute of Drug Clinical Trial/GCP Center The Affiliated Hospital of Southwest Medical University Luzhou China; 2. Hinova Pharmaceuticals Inc. Chengdu China; 3. Department of Cardiology The Affiliated Hospital of Southwest Medical University Luzhou ChinaShow moreShow less
Source PDF DOI Publisher page
241 days

A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants

Authors
Takakazu Sato; Hiroyuki Fukase; Takaaki Ishida; Arisa KarasawaShow moreShow less
Affiliations
1. Chugai Pharmaceutical Co., Ltd. Tokyo Japan; 2. Clinical Research Hospital Tokyo JapanShow moreShow less
Source PDF DOI Publisher page
277 days

Pharmacokinetic and Pharmacodynamic Bio‐Similarity of ADL‐018 to Innovator Omalizumab: A Randomized Study in Healthy Adults

Authors
Sunil Soitawala; Hiren Prajapati; Hiren Mehta; Pawan Kumar SinghShow moreShow less
Affiliations
1. Clinical Research Department Veeda Clinical Research Ltd. Mehsana Gujarat India; 2. Clinical Research Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 3. Clinical Affairs/Biometrics Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 4. Kashiv Biosciences, LLC Ahmedabad Gujarat IndiaShow moreShow less
Source PDF DOI Publisher page
126 days

An Open‐Label Study Investigating the 5‐HT 2A Receptor Occupancy of Remlifanserin (ACP‐204) With the PET Radioligand [ 18 F]Altanserin in Healthy Male Participants

Authors
Ethan S. Burstein; Christine Sandiego; Brian Raether; Xiaoshu Feng; Bryan Dirks; Mona Darwish; Peter Zhang; David S. Russell; Eugenii A. Rabiner; Sanjeev PathakShow moreShow less
Affiliations
1. Acadia Pharmaceuticals Inc. San Diego CA USA; 2. Perceptive Discovery New Haven CT USA; 3. Acadia Pharmaceuticals Inc. Princeton NJ USA; 4. Perceptive Discovery London UKShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.